Why I Would Buy Indivior Plc Instead Of Reckitt Benckiser Group Plc

Why does this Fool prefer Indivior plc (LON: INDV) to Reckitt Benckiser Group plc (LON: RB)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sometimes it can pay off to buy into spin-offs. A spin-off is formed when a corporation takes part of its business and separates it from the parent company. Perhaps the business being spun off is considered to be non-core to the parent, or management believe that the company will do better by standing on its own two feet.

Today, I’m going to look at a company spun off from the £40bn mega-cap Reckitt Benckiser (LSE: RB) at the tail end of last year — and why I’d be more inclined to buy Indivior (LSE: INDV) than its parent.

Going it Alone…

Indivior was listed as a new company at the end of last year: it is the former pharmaceutical division of Reckitt Benckiser.  The shares began life on the stock exchange trading at 150p per share. Using my 20-20 hindsight, this was a cheap price: the shares currently change hands at around 240p — that’s not a bad gain in just over six months. As you can see from the chart, the stock has trounced the FTSE 100 and the parent company.

So, what has caused its outperformance? It is possible that the market likes the current price to earnings ratio. On a trailing 12-month (TTM) basis, the shares trade on a P/E of just over 7. This means that it is currently one of the cheapest stocks in the market. As we know, however, the market looks forward. The company’s major product, Suboxone Film (used to treat people with an opioid dependence), came off-patent in 2010.  As one would expect, this has caused earnings fall from $614 million in 2011 to $363 million in 2014, while earnings are expected to fall further as the company faces increased generic-drug competition going forward.

It could also be the current product pipeline of new products to treat opioid addiction and other illnesses over the next five years that has raised investors’ attention.

Opioids are prescribed to treat acute pain; however, there is a plethora of opioid overdoses, and Indivior has several products in its pipeline that could treat opioid addiction and overdoses:

  • Monthly Buprenorphine Injection — this injection would be used to treat opioid addiction. Phase III trials were due to commence in 2015, if all goes well, the product could be launched in 2017.
  • Nasal naloxone – this is a medication used to counter the effects of opioid overdose, delivered via the nose. It could be exported beyond the US next year, with obvious benefits.

The company has several other products at various other stages of testing prior to regulatory filings. Should these be given the all-clear, I would expect the market to re rate these shares accordingly.

Never Underestimate The Moat…

Having said what a good company Indivior could be, I think that investors would be wrong to write off its parent, Reckitt Benckiser.  Whilst some more value-orientated investors may think that this company looks expensive in price-to-earnings terms, currently nearly 23 times forward earnings. You need only look to the sage Warren Buffett, who hunts for businesses that can protect their returns with an enduring ‘moat’.

For Buffett, the company needs to be able to stave off the threat of competition by erecting formidable barriers — indeed, why wouldn’t others want to try for a piece of the pie if they can see a profitable space to do business?

The word ‘moat’ is, for some, the first thing that they look for in a business.  They want to buy shares of a company that can generate market-beating profits from dominant market positions, respected brands and pricing power.

As a consumer defensive, Reckitt Benckiser operates in an extremely competitive space, yet still manages to deliver:

  • Return on capital (ROCE) – 21.2%
  • Return on equity – 25.3%
  • Operating margin – 24.5%

These quality scores make it a very difficult beast to beat.

So, Why Would I Buy Indivior?

Personally, I like smaller operators like Indivior. They can be less well researched by the market, thus creating opportunities for investors to look a little further down the leaderboard.

To me, it looks like the market is starting to warm to Indivior, with brokers becoming more positive on the stock, and importantly upgrading their earnings estimates.  This is currently not the case for its parent, Reckitt Benckiser, with brokers downgrading heir earnings expectations for 2015 and 2016. As such, I currently see Indivior as the better buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »